Order Article Reprints

Liu Y, Vorobyeva A, Xu T, Orlova A, Loftenius A, Bengtsson T, Jonasson P, Tolmachev V, Frejd FY. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics. 2021; 13(6):839. https://doi.org/10.3390/pharmaceutics13060839

Liu, Yongsheng, Anzhelika Vorobyeva, Tianqi Xu, Anna Orlova, Annika Loftenius, Theresa Bengtsson, Per Jonasson, Vladimir Tolmachev, and Fredrik Y. Frejd. 2021. "Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain" Pharmaceutics 13, no. 6: 839. https://doi.org/10.3390/pharmaceutics13060839

Liu, Y., Vorobyeva, A., Xu, T., Orlova, A., Loftenius, A., Bengtsson, T., Jonasson, P., Tolmachev, V., & Frejd, F. Y. (2021). Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics, 13(6), 839. https://doi.org/10.3390/pharmaceutics13060839